Wat is de prijs voor Novo Nordisk A/S (NOVO-B)

Het prijs van Novo Nordisk A/S (NOVO-B) is $41.14

Wat is de marktkapitalisatie voor Novo Nordisk A/S (NOVO-B)

Marktkapitalisatie voorNovo Nordisk A/S (NOVO-B) is $182.76B

Novo Nordisk A/S (NOVO-B) Aandelensplitsingen

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
2023-09-20	2:1	x2	x200
2014-01-09	5:1	x5	x100
2007-12-17	2:1	x2	x20
2001-04-11	5:2	x2.5	x10
1994-04-18	4:1	x4	x4

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

2023-09-20

2:1

x200

2014-01-09

5:1

x100

2007-12-17

2:1

x20

2001-04-11

5:2

x2.5

x10

1994-04-18

4:1

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
Eli Lilly and Company LLY.US	4	x15	US
Johnson & Johnson JNJ.US	7	x432	US
AbbVie Inc. ABBV.US	0	-	US
Roche Holding AG RO.SW	2	x10000	CH
Merck & Co., Inc. MRK.US	7	x226	US

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land